GlassScriptPhysician profile
Shonda M Asaad
NPI 1831122035
$8,598.98
in general payments reported to CMS, 2019-2025
72 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $211 · 2021: $1,111 · 2022: $1,721 · 2023: $1,890 · 2024: $1,431 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,891 · Education: $86.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,891.32 |
| Education | $86.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $763.36 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $478.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $448.28 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Pfizer INC. | $423.99 | 2019-2025 | |
| Celgene Corporation | $391.84 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $344.21 | 2019-2025 | Jakafi, Pemazyre |
| Daiichi Sankyo INC. | $331.75 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $313.00 | 2019-2025 | Ninlaro, Iclusig, Fruzaqla |
| Janssen Biotech, INC. | $311.30 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Genzyme Corporation | $281.56 | 2021-2025 | |
| Eisai INC. | $246.04 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $229.54 | 2021-2025 | Enhertu, Lynparza, Calquence |
| Gilead Sciences, INC. | $191.44 | 2021-2025 | Trodelvy |
| Seagen INC. | $179.54 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Amgen INC. | $156.95 | 2021-2023 | Lumakras, Kyprolis, Blincyto |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $152.20 | 2023-2025 | Venclexta |
| Astellas Pharma US INC | $149.44 | 2019-2025 | Xospata, Padcev |
| Genentech USA, INC. | $143.21 | 2021-2025 | Polivy, Venclexta, Lunsumio |
| Lilly USA, LLC | $140.26 | 2021-2024 | Jaypirca, Retevmo, Verzenio |
| Beigene USA, INC. | $139.36 | 2022-2025 | Brukinsa |
| Exelixis INC. | $134.55 | 2020-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $126.90 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Emd Serono, INC. | $117.03 | 2020-2025 | Bavencio |
| Servier Pharmaceuticals LLC | $115.45 | 2021-2024 | |
| Tersera Therapeutics LLC | $111.65 | 2019-2025 | Xermelo, Quzyttir |
| Deciphera Pharmaceuticals INC. | $105.90 | 2021-2025 | Qinlock, Romvimza |
| Dova Pharmaceuticals | $97.69 | 2019 | |
| Stemline Therapeutics INC. | $96.50 | 2023-2025 | Orserdu |
| Genmab U.S., INC. | $95.65 | 2022-2025 | Tivdak, Epkinly |
| Shionogi INC | $93.22 | 2019 | |
| Array Biopharma INC | $91.44 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Adc Therapeutics America, INC. | $81.33 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.87 | 2021-2024 | Gilotrif |
| Pharmacyclics LLC, An Abbvie Company | $80.08 | 2021-2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $72.26 | 2021-2025 | Libtayo |
| Taiho Oncology, INC. | $69.99 | 2023-2025 | Lonsurf |
| Geron Corporation | $66.43 | 2024-2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $65.05 | 2022-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $64.30 | 2022-2024 | Zepzelca |
| Pharmaessentia USA Corporation | $60.55 | 2023-2024 | Besremi |
| Karyopharm Therapeutics INC. | $53.40 | 2020-2025 | Xpovio |
| Epizyme, INC. | $49.91 | 2021 | |
| Sirtex Medical INC | $48.56 | 2022 | |
| Fennec Pharmaceuticals, INC. | $47.37 | 2025 | Fyarro |
| Sun Pharmaceutical Industries INC. | $47.23 | 2023-2024 | Yonsa |
| Beone Medicines USA, INC. | $44.15 | 2025 | Brukinsa, Tevimbra |
| Azurity Pharmaceuticals, INC. | $41.07 | 2024-2025 | Vivimusta, Danziten |
| Tesaro, INC. | $40.52 | 2019 | |
| Sobi, INC | $39.10 | 2023-2025 | |
| Acrotech Biopharma INC. | $39.01 | 2023-2024 | Beleodaq |
| Adaptive Biotechnologies Corporation | $38.13 | 2024-2025 | Clonoseq |
| G1 Therapeutics, INC. | $35.97 | 2022-2023 | Cosela |
| Blueprint Medicines Corporation | $35.76 | 2021 | |
| Pharmacosmos Therapeutics INC. | $33.37 | 2024-2025 | Cosela, Monoferric |
| Puma Biotechnology, INC. | $31.98 | 2020-2023 | |
| Alnylam Pharmaceuticals INC. | $29.33 | 2023 | Givlaari |
| Eusa Pharma (US) LLC | $28.35 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.67 | 2025 | |
| Tempus Ai, INC | $24.86 | 2024 | Xt Cdx |
| Springworks Therapeutics, INC. | $23.43 | 2025 | Ogsiveo |
| Foundation Medicine, INC. | $23.17 | 2022 | |
| Secura Bio, INC. | $23.07 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $20.20 | 2019 | |
| Apellis Pharmaceuticals, INC. | $18.09 | 2023 | Empaveli |
| Accord Healthcare, INC. | $16.17 | 2024 | |
| Immunogen, INC. | $15.70 | 2023 | Elahere |
| Coherus Oncology, INC. | $14.88 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $14.67 | 2019 | |
| Verastem, INC. | $14.55 | 2019 | |
| Spectrum Pharmaceuticals INC. | $13.76 | 2025 | Rolvedon |
| Aveo Pharmaceuticals, INC. | $13.56 | 2021 | |
| Clovis Oncology, INC. | $10.73 | 2019 |
Drugs and devices associated with these payments
Keytruda $488Reblozyl $216Lenvima $171Enhertu $162Lynparza $142Tecvayli $127Opdivo $123Tukysa $120Brukinsa $119Xtandi $106Orserdu $96.50Ninlaro $93.66Orgovyx $90.92Kisqali $89.06Ibrance $84.20Talzenna $83.71Welireg $82.16Qinlock $78.85Elahere $74.61Braftovi $74.61Pluvicto $73.84Venclexta $73.61Epkinly $71.62Xospata $70.11Lonsurf $69.99Padcev $69.47Injectafer $67.88Imbruvica $66.73Rytelo $66.43Jakafi $64.37Comirnaty $63.40Zejula $62.29Jemperli $62.29Cabometyx $61.74Darzalex $61.69Trodelvy $61.36Besremi $60.55Mektovi $58.48Tibsovo $57.43Opdualag $56.98Fabhalta $55.18Keytruda Qlex $54.57Tivdak $53.17Xermelo $51.46Libtayo $51.21Iclusig $50.81Zepzelca $49.18Fyarro $47.37Datroway $47.36Yonsa $47.23Paxlovid $44.65Talvey $42.86Ojjaara $42.33Vivimusta $41.07Beleodaq $39.01Fruzaqla $38.69Adcetris $38.67Clonoseq $38.13Polivy $37.75Xpovio $36.96Cosela $35.93Lutathera $33.52Lumakras $31.09Givlaari $29.33Tabrecta $27.04Nubeqa $26.67Inqovi $26.38Sarclisa $25.54Gilotrif $25.41Xt Cdx $24.86Pemazyre $24.38Ogsiveo $23.43Augtyro $23.37Vonjo $22.76Kyprolis $22.59Blincyto $22.59Ultomiris $21.91Pomalyst $21.57Elrexfio $20.67Danziten $20.46Romvimza $20.02Quzyttir $18.68Verzenio $18.50Jaypirca $18.50Retevmo $18.50Tevimbra $18.41Empaveli $18.09Blenrep $16.72Idhifa $16.39Doptelet $16.34Rybrevant $16.30Monoferric $16.21Camcevi $16.17Lunsumio $16.13Xgeva $16.06Nplate $16.06Calquence $15.71Bavencio $15.61Inlyta $14.73Zynlonta $14.66
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shonda Asaad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.